Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

MONSil-AD The Mechanisms of neuronal silencing in Alzheimer’s Disease – investigation of cellular and network mechanisms in mouse models of β-amyloidosis

Coordinator
Klinikum Der Technischen Universität München (tum Klinikum), Germany
Runs
1 January 2026 to 31 December 2030
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101221828

What the project is doing

In the project's own words, from its summary on CORDIS.

Alzheimer’s disease (AD) is defined by pathological brain changes, including the accumulation of β-amyloid and tau deposits over decades. In addition, data in human patients and rodent models indicate that neuronal dysfunctions, i.e., altered action potential firing rates, are further hallmarks of AD. Two forms of neuronal dysfunctions exist - neuronal hyperactivity at early stages, followed later by neuronal silencing.

The causes of neuronal hyperactivity have been widely studied. However, the mechanisms of neuronal silencing are still incompletely understood, likely due to the high complexity of interdependent brain changes in late AD stages. MONSil-AD aims to unravel the multifactorial pathways leading to neuronal silencing in AD mouse models. My preliminary data indicate that silencing co-occurs with emergent tauopathy, loss of dendritic spines, and decreased presynaptic inputs in mouse models of β-amyloidosis.

Moreover, the soluble ectodomain of the microglial ‘triggering receptor expressed on myeloid cells 2’ (sTREM2), which is upregulated in AD, suppresses neuronal activity. Based on these findings, I will investigate whether synaptic uncoupling from the circuit causes the silencing of individual neurons (aim 1) and test if intracellular tau accumulation silences neurons on a cellular level (aim 2). In addition, I will explore the contribution of sTREM2 to neuronal silencing in AD (aim 3) and the interactions between the three mechanisms.

To reach the ambitious aims of MONSil-AD, I have implemented cutting-edge in vivo two-photon imaging techniques and developed specialized protocols enabling me, for the first time, to provide a comprehensive picture of the mechanisms leading to neuronal silencing in AD. In addition, MONSil-AD may have direct clinical implications as a basis for the development of an activity-based screening tool for the early non-invasive detection of AD and the development of targeted treatment strategies to prevent neuronal silencing.

Topics

Who is involved

OrganisationCityCountryRole
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI